A biochemist and science journalist, she has covered the biotech industry for more than 20 years. “The Covid pandemic and the successful development of vaccines have changed a lot in terms of the acceptance of these issues. The industry is swimming in money, and more research is being done than ever before.” At the same time, he said, there has been a positive trend in new drug approvals for 15 years. “If we can do it with Covid, why not do it with cancer? Why not with Parkinson’s or Alzheimer’s?